The role of biologics in treatment of ANCA-associated vasculitis

References

• Falk RJ, Gross WL, Guillevin L, Hoffman GS, Jayne DRW, Jennette JC, Kallenberg CGM, Luqmani R, Mahr AD, Matteson EL, Merkel PA, Specks U, Watts RA, for the American College of Rheumatology, the American Society of Nephrology, and the European League Against Rheumatism. Arthritis Rheum 2011;63: 863–864.
   PubMed Web of Science ®Google Scholar
• Ntatsaki E, Watts RA, Scott DG. Epidemiology of ANCA-asso-ciated vasculitis. Rheum Dis Clin North Am. 2010;36:447–61.
   PubMed Web of Science ®Google Scholar
• Fujimoto S, Watts RA, Kobayashi S, Suzuki K, Jayne DRW, Scott GDI, Hashimoto H, Nunoi H. Comparison of the epide-miology of antineutrophil cytoplasmic antibody (ANCA)-asso-ciated vasculitis between Japan and UK. Rheumatology. 2011;50:1916–20.
   PubMed Web of Science ®Google Scholar
• Walton EW. Giant-cell granuloma of the respiratory tract (We-gener's granulomatosis). Br Med J. 1958;2:265–9.
   PubMed Web of Science ®Google Scholar
• Fauci A, Wolff S. Wegeners granulomatosis: studies in 18 patients and a review of the literature. Medicine. 1973;52: 535–61.
   PubMed Web of Science ®Google Scholar
• Little MA, Nightingale P, Verburh CA, on behalf of the European Vasculitis Study (EUVAS) Group, et al. Early mortality in sys-temic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis. 2010;69:1036–43.
   Google Scholar
• Flossman 0, Berden A, de Groot K, et al. Long term patient survival in ANCA associated vasculitis. Ann Rheum Dis. 2011;70:488–94.
   Google Scholar
• Lapraik C, Watts RA, Scott DG. BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology. 2007;46:1615–6.
   Google Scholar
• Mukhtyar C, Guillevin L, Cid M, et al. EULAR recommenda-tions for the management of primary small and medium vascu-litis. Ann Rheum Dis. 2009;68:310–7.
   PubMed Web of Science ®Google Scholar
• Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349:36–44.
   PubMed Web of Science ®Google Scholar
• de Groot K, Rasmussen N, Bacon P, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remis-sion in early systemic antineutrophil cytoplasmic antibody asso-ciated vasculitis. Arthritis Rheum. 2005;52:2461–8.
   PubMed Web of Science ®Google Scholar
• de Groot K, Harper L, Jayne DR, et al. Pulse versus oral cyclo-phosphamide for induction of remission in anti neutrophil cyto-plasmic antibody associated vasculitis: a randomized trial. Ann Intern Med. 2009;150:670–80.
   PubMed Web of Science ®Google Scholar
• Jayne DR, Gaskin G, Rasmussen N, et al. Randomized trial of plasma exchange and high dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007;18:2180–8.
   PubMed Web of Science ®Google Scholar
• Harper L, Savage COS. Pathogenesis of ANCA-associated sys-temic vasculitis. J Pathol. 2000;190:349–59.
   PubMed Web of Science ®Google Scholar
• Gross WL. Immunopathology and new therapeutic considerations in ANCA-associated vascufitides. Autoimmun Rev. 2004;3(Suppl 1): S47–8.
   PubMedGoogle Scholar
• Hess C, Sadallah S, Schifferli JA. Induction of neutrophil responsiveness to myeloperoxidase antibodies by their exposure to supernatant of degranulated autologous neutrophils. Blood. 2000;96:2822–7.
   Google Scholar
• Kettritz R, Schreiber A, Luft FC, Haller H. Role of mitogenac-tivatedprotein kinases in activation of human neutrophils by an-tineutrophil cytoplasmic antibodies. J Am Soc Nephrol. 2001;12:37–46.
   PubMed Web of Science ®Google Scholar
• Porges AJ, Redecha PB, Kimberly WT, Csernok E, Gross WL, Kimberly RP. Anti-neutrophil cytoplasmic antibodies engage and activate human neutrophils via Fc gamma RIIa. J Immunol. 1994;153:1271–80.
   PubMed Web of Science ®Google Scholar
• Harper L, Radford D, Plant T, Drayson M, Adu D, Savage CO. IgG from myeloperoxidase-antineutrophil cytoplasmic antibody-positive patients stimulates greater activa-tion of primed neutro-phils than IgG from proteinase 3-antineutrophil cytoplasmic antibody-positive patients. Arthritis Rheum. 2001;44:921–30.
   PubMedGoogle Scholar
• Booth AD, Jefferson H.T, Ayliffe W, Andrews PA, Jayne DR. Safety and efficacy of TNFalpha blockade in relapsing vasculitis. Ann Rheum Dis. 2002;61:559.
   PubMedGoogle Scholar
• Lamprecht P, Voswinkel J, Lilienthal T, Nolle B, Heller M, Gross WL, et al. Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxf). 2002;41:1303–7.
   PubMed Web of Science ®Google Scholar
• Booth A, Harper L, Hammad T, Bacon P, Griffith M, Levy J, et al. Prospective study of TNF alpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vascu-litis. J Am Soc Nephrol. 2004;15:717–21.
   PubMed Web of Science ®Google Scholar
• Bartolucci P, Ramanoelina J, Cohen P, Mahr A, Godmer P, Le Hello C, et al. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxf). 2002;41: 1126–32.
   Google Scholar
• Mukhtyar C, Luqmani R. Current state of tumour necrosis factor blockade in Wegener's granulomatosis. Ann Rheum Dis. 2005;64(Suppl 4):31–6.
   Google Scholar
• Morgan MD, Drayson MT, Savage CO, Harper L. Addition of infliximab to standard therapy for ANCA-associated vasculitis. Nephron Clin Pract. 2011;117(2):c89–97.
   PubMedGoogle Scholar
• Stone JH, Uhlfelder ML, Hellmann DB, Crook S, Bedocs NM, Hoffman GS. Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety. Arthritis Rheum. 2001;44:1149–54.
   PubMed Web of Science ®Google Scholar
• The Wegener's Granulomatosis Etanercept (WGET) Research Group. Etanercept plus standard therapy for Wegener's granu-lomatosis. N Engl J Med. 2005;352:351–61.
   Google Scholar
• Laurino S, Chaudhry A, Booth A, Conte G, Jayne D. Prospective study of TNFalpha blockade with adalimumab in ANCA-asso-ciated systemic vasculitiswith renal involvement. Nephrol Dial Transpl. 2010;25(10):3307–14.
   Google Scholar
• Komocsi A, Lamprecht P, Csemok E, Mueller A, Ho11-Ulrich K, Seitzer U, et al. Peripheral blood and granuloma CD4(+)CD28(2) T cells are a major source of interferon-gamma and tumor necrosis factor-a in Wegener's granulomatosis. Am J Pathol. 2002;160: 1717–24.
   Google Scholar
• Popa ER, Franssen CF, Limburg PC, Huitema MG, Kallenberg CG, Tervaert JW. In vitro cytokine production and proliferation of T cells from patients with anti-proteinase 3 and anti-myeloperoxidase-associated vasculitis, in response to proteinase 3 and myeloperoxidase. Arthritis Rheum. 2002;46:1894–904.
   PubMedGoogle Scholar
• Isaacs JD, Manna VK, Rapson N, Bulpitt KJ, Hazleman BL, Matteson EL, et al. CAMPATH-1H in rheumatoid arthritis-an intravenous dose-ranging study. Br J Rheumatol. 1996;35: 231–40.
   PubMedGoogle Scholar
• Walsh M, Chaudhry A, Jayne D. Long-term follow-up of relapsing/refractory antineutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody ale-mtuzumab (CAMPATH-1H). Ann Rheum Dis. 2008;67: 1322–7.
   Google Scholar
• Kim S, Marigowda G, Oren E, Israel E, Wechsler ME. Mepolizumab as a steroid sparing treatment option in patients with Churg-Strauss syndrome. J Allergy Clin Immunol. 2010; 125:1336–43.
   Google Scholar
• Smith KG, Jones RB, Burns SM, Jayne DR. Long-term com-parison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re treat-ment. Arthritis Rheum. 2006;54:2970–82.
   PubMed Web of Science ®Google Scholar
• Eriksson P. Nine patients with anti-neutrophil cytoplasmic anti-body-positive vasculitis successfully treated with rituximab. J Intern Med. 2005;257:540–8.
   PubMed Web of Science ®Google Scholar
• Keogh KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, Specks U. Rituximab for refractory Wegener's granuloma-tosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med. 2006;173:180–7.
   PubMed Web of Science ®Google Scholar
• Stasi R, Stipa E, Del Poeta G, Amadori S, Newland AC, Provan D. Long-term observations of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with ritux-imab. Rheumatology (Oxf). 2006;45:1432–6.
   PubMed Web of Science ®Google Scholar
• Keogh KA, Wylam ME, Stone JH, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vascu-litis. Arthritis Rheum. 2005;52:262–8.
   PubMed Web of Science ®Google Scholar
• Tamura N, Matsudaira R, Hirashima M, Ikeda M, Tajima M, Nawata M, et al. Two cases of refractory Wegener's granulo-matosis successfully treated with rituximab. Intern Med. 2007;46: 409–14.
   PubMed Web of Science ®Google Scholar
• Brihaye B, Aouba A, Pagnoux C, Cohen P, Lacassin F, Guillevin L. Adjunction of rituximab to steroids and immunosuppressants for refractory/relapsing Wegener's granulomatosis: a study on 8 patients. Clin Exp Rheumatol. 2007;25(Suppl 44):523–7.
   PubMedGoogle Scholar
• Omdal R, Wildhagen K, Hansen T, Gunnarsson R, Kristoffersen G. Anti-CD20 therapy of treatment-resistant Wegener's granu-lomatosis: favourable but temporary response. Scand J Rheu-matol. 2005;34: 229–32.
   Google Scholar
• Ferraro AJ, Day CJ, Drayson MT, Savage CO. Effective thera-peutic use of rituximab in refractory Wegener's granulomatosis. Nephrol Dial Transpl. 2005;20:622–5.
   PubMed Web of Science ®Google Scholar
• Cartin-Ceba R, Keogh KA, Specks U, Sethi S, Fervenza FC. Riximab for the treatment of Churg Strauss syndrome with renal involvement. Nephrol Dial Transpl. 2011;26:2865–71.
   Google Scholar
• Stone JH, Merkel PA, Spiera R, et al. Rituximaab versus cyclo-phosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363:221–32.
   PubMed Web of Science ®Google Scholar
• Specks U, Stone JH, for the RAVE-ITN Research Group. Long term efficacy and safety of the RAVE trial. Clin Exp Immunol. 2011;164\(Suppl 1):65. (abstract).
   Google Scholar
• Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363:211–20.
   PubMed Web of Science ®Google Scholar
• Jones RB, Walsh M, Jayne DRW, on behalf of the European Vasculitis Study Group. Two year follow up results from a ran-domised trial of RTX versus CyP for ANCA-associated vascu-litis: RITUXVAS. Clin Exp Immunol. 2011;164\(Suppl 1):57. (abstract).
   Google Scholar
• Guerry MJ, Brogan P, Bruce IN, et al. Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody associated vasculitis. Rheumatology 2011. First published online May 25, 2011. doi:10.1093/rheumatology/ker150.
   Google Scholar
• Jones RB, Ferraro AJ, Chaudhry AN, Brogan P, Salama AD, Smith KGC, Savage COS, Jayne DRW. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic anti-body-associated vasculitis. Arthritis Rheum. 2009;60:2156–68.
   PubMed Web of Science ®Google Scholar
• Major EO. Progressive multifocal Leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med. 2010; 61:34–47.
   Web of Science ®Google Scholar
• Helena M, Jones RB, Smith RM, Catapano F, Chaudhry A, Jayne DRW. Hypogammaglobuminaemia and infections following RTX therapy for systemic vasculitis and SLE. Clin Exp Immunol. 2011;164\(Suppl 1):59. (abstract).
   Google Scholar
• Tesfa D, Aleganova S, Hägglund H, Sander B, Fade11 B, Hafström I, Palmblad J. Late on-set neutropaenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Arthritis Rheum 2011. doi: 10.1002/art.30427, [Epub ahead of print].
   Google Scholar
• Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheu-matoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis. 2009;68(1):25–32.
   Google Scholar